PUBBLICAZIONI - DOTT. DAVID VIOLA - SPECIALISTA IN ENDOCRINOLOGIA - UNIVERSITA' DI PISA

Menu principale:

PUBBLICAZIONI

Pubblicazioni 1- 5 Pubblicazioni 6 - 10 Pubblicazioni 11 - 14

1. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9.

2. Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, Viola D, Elisei R. Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. J Clin Endocrinol Metab. 2009 May;94(5):1618-22.

3. Molinaro E, Viola D, Passannanti P, Agate L, Lippi F, Ceccarelli C, Pinchera A, Elisei R. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging. 2009 Oct;53(5):490-502. Review.

4. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf). 2011 Feb;74(2):241-7.

5. Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, Viola D, Piaggi P, Vitti P, Pinchera A, Elisei R. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer. 2011 Sep 20;18(5):603-12.

6. Bertini V, Viola D, Vitti P, Simi P, Valetto A. An idic(15) associated with POF (premature ovarian failure): molecular cytogenetic definition of a case and review of the literature. Gene. 2012 Jul 15;503(1):123-5.

7. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab. 2012 Sep;97(9):E1758-65.

8. Molinaro E, Pieruzzi L, Viola D. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. J Endocrinol Invest. 2012;35(6 Suppl):16-20. Review.

9. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8.

10. Minuto MN, Miccoli M, Viola D, Ugolini C, Giannini R, Torregrossa L, Antonangeli L, Aghini-Lombardi F, Elisei R, Basolo F, Miccoli P. Incidental versus clinically evident thyroid cancer: a 5-year follow-up study. Head Neck. 2013 Mar;35(3):408-12.

11. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013 Apr 10;309(14):1493-501.

12. Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab. 2013; 98(7):2693-700.

13. Viola D, Cappagli V, Elisei R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol. 2013 Aug;9(8):1083-92.

14. Ugolini C, Elisei R, Proietti A, Pelliccioni S, Lupi C, Borrelli N, Viola D, Leocata P, Vitti P, Miccoli P, Toniolo A, Basolo F. FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to 131-iodine treatment. Thyroid. 2013 Aug 5.